Laura Manna

University of Naples, Italy

Title: A clinical trial to evaluate the safety and immunogenicity of a novel DNA vaccine used as immunotherapy during leishmaniasis


Laura Manna has completed her PhD at the age of 28 years from Naples University and Postdoctoral studies from Naples University School of Veterinary Medicine. From 2005 she is a Researcher of Department of Veterinary Medicine and Animal Productions of University of Naples. Her research interest is to develop a protective vaccine for the prevention and treatment of leishmaniasis. She has published more than 25 papers in reputed journals.


Twenty leishmaniotic dogs from a leishmaniasis-endemic area (Naples, Italy) were enrolled in a clinical trial and were randomly assigned to receive three consecutive subcutaneous injections of vaccine at 10-days intervals (n=1020), saline placebo (n=1020). The vaccine was safe and well tolerated. Leishmania DNA load, IFAT, INF- and IL4 mRNA expression levels were tested before and after the immunotherapy, every 3 months for a period of 12 months. Analysis of the data indicated that the vaccine was safe and immunogenic in CVL dogs.